Overview
Compare with Verrica Pharmaceuticals Inc., Sunshine Biopharma Inc. or LFTD PARTNERS INC., or pick any stock.
- TickerETST on OTC2
- IndustryPharmaceutical Preparations2
- HeadquartersNewark, United States2
- Incorporated inFL4
- Business address8950 Sw 74Th Ct, Suite 101, Miami, Fl 331564
- Filer categoryNon-accelerated filer, Smaller reporting company4
- Legal formCorporation2
- LEI5493005PQQBQWR41CT232
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O Nevada Business Center, LLC, 89703 Carson City, United States2
See how the biggest companies compare on our leaderboards
23, 2010, and subsequently redomiciled to the State of Florida on June 27, 2022, headquartered in Miami, Florida.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
71.4%Gross margin3
10.2%Net margin3
7.8%Revenue growth, 20263
51.8%Return on equity3
$1.2MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Sale of Pharmaceutical Products and Medical Consultations brought in 92% of the revenue Earth Science Tech, Inc. broke down this way in fiscal 2026.
Products and services by year
| Products and services | 2025 | 2026 |
|---|---|---|
| Sale of Pharmaceutical Products and Medical Consultations | $30.0M | $32.9M |
| Shipping and Handling | $3.1M | $2.5M |
| Other. | $300.8K |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue29¢$10.2M
- Selling, general and admin10¢$3.6M
- Other costs50¢$17.8M
- Income tax1¢$511.7K
- Profit10¢$3.6M
Out of $35.7M in revenue.3
Where each dollar of operating cash went, fiscal 2026
- Capital spending39¢$756.6K
- Share buybacks24¢$471.4K
- Kept or used elsewhere37¢$712.8K
Out of $1.9M of cash from operations.3
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Revenue | $35.7M | $33.1M |
| Cost of Goods Sold | $10.2M | $8.8M |
| Gross Profit | $25.5M | $24.3M |
| Salaries Expense | $13.8M | $14.1M |
| Selling general and administrative expenses | $3.6M | $4.2M |
| Bank charges | $1.0M | $1.1M |
| Advertising & marketing | $2.8M | $836.9K |
| Legal and professional fees | $221.2K | $305.9K |
| Insurance | $168.4K | $180.3K |
| Operating lease cost | $180.8K | $98.4K |
| Depreciation and amortization | $284.4K | $54.0K |
| Utilities | $130.8K | $39.7K |
| Total Expenses | $22.2M | $20.9M |
| Dividend and interest income | $15.5K | $9.1K |
| Net realized gain on sale of investments | $671.5K | $300.2K |
| Unrealized Gain (Loss) on fair value changes of investments | -$957.1K | -$365.7K |
| Other | $67.2K | |
| Interest Expense | -$16.3K | -$21.2K |
| Net Income before taxes | $3.1M | $3.4M |
| Income Taxes | -$511.7K | $116.8K |
| Net Income | $3.6M | $3.3M |
| Net Income/(Loss) attributed to non-controlling interest | -$29.8K | |
| Net Income available to common stockholders | $3.6M | $3.3M |
| Earnings per common share - Basic | $0.01 | $0.01 |
| Earnings per common share - Diluted | $0.01 | $0.01 |
| Weighted average number of shares outstanding- Basic | 293.1M shares | 303.5M shares |
| Weighted average number of shares outstanding- Diluted | 293.1M shares | 303.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash and cash equivalents | $796.8K | $1.5M | |
| Accounts receivable, net | $356.1K | $129.1K | |
| Equity securities | $1.4M | $645.4K | |
| Inventory | $682.1K | $503.9K | |
| Long lived assets, available for sale | $371.7K | ||
| Prepaid Expenses and other current assets | $154.5K | $358.8K | |
| Total Current Assets | $3.7M | $3.1M | |
| Property and Equipment, net | $1.5M | $1.4M | |
| Right of use assets, net | $95.3K | $172.4K | |
| Intangible assets, net | $208.2K | $96.9K | |
| Deferred tax asset, net | $772.3K | ||
| Goodwill | $2.7M | $2.3M | |
| TOTAL ASSETS | $9.0M | $7.1M | |
| Accounts payable | $681.9K | $492.4K | |
| Accrued expenses and other payables | $1.2M | $2.3M | |
| Current portion of operating lease obligations | $96.2K | $121.9K | |
| Current portion of loans & obligations | $30.6K | ||
| Short-term business loans | $179.5K | ||
| Total Current Liabilities | $1.9M | $3.1M | |
| Lease Liability | $37.9K | ||
| Loans and Obligations | $31.4K | ||
| Total Liabilities | $1.9M | $3.2M | |
| Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of March 31, 2026, and March 31, 2025, respectively | $1.0K | $1.0K | |
| Common stock, par value $0.001 per share, 300,000,000 shares authorized; 291,324,607 shares issued and outstanding as of March 31, 2026, and 295,347,903 issued and 294,302,607 outstanding as of March 31, 2025 | $291.3K | $295.3K | |
| Additional Paid in Capital | $30.8M | $31.5M | |
| Accumulated Deficit | -$24.1M | -$27.7M | |
| Treasury Stock, at cost (0 and 1,045,296 shares as of March 31, 2026, and March 31, 2025, respectively) | -$186.4K | ||
| Total Stockholders Equity | $7.0M | $3.9M | $2.2M |
| Non-Controlling Interest | $30.3K | ||
| Total Equity | $7.0M | $3.9M | |
| TOTAL LIABILITIES AND EQUITY | $9.0M | $7.1M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 1.0M shares | 1.0M shares | |
| Preferred stock, shares issued | 1.0M shares | 1.0M shares | |
| Preferred stock, shares outstanding | 1.0M shares | 1.0M shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, shares issued | 291.3M shares | 295.3M shares | |
| Common stock, shares outstanding | 291.3M shares | 294.3M shares | |
| Treasury common shares | 0 shares | 1.0M shares |
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash and cash equivalents | $796.8K | $1.5M | |
| Accounts receivable, net | $356.1K | $129.1K | |
| Equity securities | $1.4M | $645.4K | |
| Inventory | $682.1K | $503.9K | |
| Long lived assets, available for sale | $371.7K | ||
| Prepaid Expenses and other current assets | $154.5K | $358.8K | |
| Total Current Assets | $3.7M | $3.1M | |
| Property and Equipment, net | $1.5M | $1.4M | |
| Right of use assets, net | $95.3K | $172.4K | |
| Intangible assets, net | $208.2K | $96.9K | |
| Deferred tax asset, net | $772.3K | ||
| Goodwill | $2.7M | $2.3M | |
| TOTAL ASSETS | $9.0M | $7.1M | |
| Accounts payable | $681.9K | $492.4K | |
| Accrued expenses and other payables | $1.2M | $2.3M | |
| Current portion of operating lease obligations | $96.2K | $121.9K | |
| Current portion of loans & obligations | $30.6K | ||
| Short-term business loans | $179.5K | ||
| Total Current Liabilities | $1.9M | $3.1M | |
| Lease Liability | $37.9K | ||
| Loans and Obligations | $31.4K | ||
| Total Liabilities | $1.9M | $3.2M | |
| Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of March 31, 2026, and March 31, 2025, respectively | $1.0K | $1.0K | |
| Common stock, par value $0.001 per share, 300,000,000 shares authorized; 291,324,607 shares issued and outstanding as of March 31, 2026, and 295,347,903 issued and 294,302,607 outstanding as of March 31, 2025 | $291.3K | $295.3K | |
| Additional Paid in Capital | $30.8M | $31.5M | |
| Accumulated Deficit | -$24.1M | -$27.7M | |
| Treasury Stock, at cost (0 and 1,045,296 shares as of March 31, 2026, and March 31, 2025, respectively) | -$186.4K | ||
| Total Stockholders Equity | $7.0M | $3.9M | $2.2M |
| Non-Controlling Interest | $30.3K | ||
| Total Equity | $7.0M | $3.9M | |
| TOTAL LIABILITIES AND EQUITY | $9.0M | $7.1M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 1.0M shares | 1.0M shares | |
| Preferred stock, shares issued | 1.0M shares | 1.0M shares | |
| Preferred stock, shares outstanding | 1.0M shares | 1.0M shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, shares issued | 291.3M shares | 295.3M shares | |
| Common stock, shares outstanding | 291.3M shares | 294.3M shares | |
| Treasury common shares | 0 shares | 1.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Net Income | $3.6M | $3.3M |
| Depreciation and amortization | $284.4K | $54.0K |
| Unrealized loss on investments | $957.1K | $365.7K |
| Realized gain on sale of investments | -$671.5K | -$300.2K |
| Accounts receivable | -$227.0K | $106.4K |
| Prepaid expenses and other current assets | -$120.8K | -$349.5K |
| Inventory | -$141.5K | -$188.2K |
| Deferred tax asset | -$772.3K | |
| Accounts payable and accrued expenses and other | -$968.4K | $1.4M |
| Net cash provided by operating activities | $1.9M | $4.4M |
| Purchases of property and equipment, intangibles and long-lived assets available for sale | -$756.6K | -$753.2K |
| Purchase of investments | -$7.6M | -$4.3M |
| Sale of investments | $6.6M | $3.6M |
| Cash used for assets acquisition, net of cash acquired | -$147.6K | -$417.2K |
| Net cash used in investing activities | -$1.9M | -$1.9M |
| Payments on loans and obligations | -$241.5K | -$429.1K |
| Proceeds from loan payable | $179.5K | |
| Repurchase of common stock | -$471.4K | -$1.5M |
| Net Cash used in financing activities | -$712.9K | -$1.7M |
| Net increase (decrease) in cash and cash equivalents | -$676.4K | $775.5K |
| Cash paid for interest | $16.3K | $21.2K |
| Cash paid for income taxes | $152.6K | $28.3K |
| Initial recognition of right of use asset | $104.9K | $100.3K |
No quarter-by-quarter statement was filed.
Corporate structure
Earth Science Tech, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Earth Science Tech, Inc.
- Giorgio R. Saumat Filed SCHEDULE 13G on Earth Science Tech, Inc., latest Jun 22, 2026
- Mario Portela Filed SC 13G on Earth Science Tech, Inc., latest Dec 21, 2022
- Jose Damian Rodriguez Filed SC 13G on Earth Science Tech, Inc., latest Dec 13, 2022
- Earth Science Tech, Inc. Newark, Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Earth Science Tech, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated depreciation | $312.2K3 Mar 31, 2026 | $87.5K3 Mar 31, 2025 | +256.9% |
| Property and equipment, net | $1.5M3 Mar 31, 2026 | $1.4M3 Mar 31, 2025 | +9.7% |
| Operating-lease assets (leased space) | $95.3K3 Mar 31, 2026 | $172.4K3 Mar 31, 2025 | −44.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $796.8K3 Mar 31, 2026 | $1.5M3 Mar 31, 2025 | −45.9% |
| Equity securities at fair value | $1.4M3 Mar 31, 2026 | $645.4K3 Mar 31, 2025 | +110.7% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $2.7M3 Mar 31, 2026 | $2.3M3 Mar 31, 2025 | +15.3% |
| Intangible assets, net (excluding goodwill) | $208.2K3 Mar 31, 2026 | $96.9K3 Mar 31, 2025 | +114.9% |
| Accumulated amortization | -$91.1K3 Mar 31, 2026 | -$18.6K3 Mar 31, 2025 | −388.7% |
| Finite-lived intangibles, net | $208.2K3 Mar 31, 2026 | $96.9K3 Mar 31, 2025 | +114.9% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $682.1K3 Mar 31, 2026 | $503.9K3 Mar 31, 2025 | +35.3% |
| Raw materials | $612.8K3 Mar 31, 2026 | $411.8K3 Mar 31, 2025 | +48.8% |
| Finished goods | $69.2K3 Mar 31, 2026 | $92.1K3 Mar 31, 2025 | −24.8% |
Properties, in its own words
The Company’s Subsidiaries RxCompound and Mister Meds use a variety of pharmaceutical compounding equipment in its operations. Most of the equipment used by the Company is owned outright by the Company, but the Company does lease certain equipment. The leases for such equipment contain terms that are customary in the industry in which the Company operates. On March 31, 2026, the Company had approximately $1,520,000 in property and equipment net.
Item 2 of the 10-K filed Jun 18, 2026.5
Leadership
Who has led Earth Science Tech, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
201520202025
- Chief executive officerGiorgio R. Saumat Feb 17, 2023 to now15
- Chief executive officerMichel Aube Dec 6, 2018 to Dec 6, 201816
- Chief executive officerMatthew Cohen May 19, 2015 to May 19, 201517
- Chief executive officerHarvey Katz Dec 31, 2014 to Dec 31, 201418
- ChairNickolas Salomon Tabraue Dec 6, 2018 to Dec 6, 201819
- PresidentNickolas Salomon Tabraue Dec 6, 2018 to Dec 6, 201819
- PresidentHarvey Katz Mar 30, 2015 to Mar 30, 201520
- PresidentIssa El-Cheikh Apr 16, 2014 to Apr 16, 201421
- Chief financial officerErnesto L. Flores May 21, 2024 to now22
- Chief financial officerWendell Hecker Dec 6, 2018 to Dec 6, 201823
- Chief financial officerMatthew Cohen May 19, 2015 to May 19, 201517
- Chief operating officerMario Guillermo Tabraue May 8, 2024 to now24
- Chief operating officerGregg Gagan Hunter Dec 6, 2018 to Dec 6, 201825
- Chief operating officerThomas H. Wright May 27, 2015 to May 27, 201526
Board members and other officers (12)
- Independent DirectorEmiliano Curia Jan 22, 2025 to now27
- Chief Technology OfficerChristopher Alan Rose Apr 30, 2024 to now28
- Chief Sales OfficerDavid Barbash May 9, 2019 to May 9, 201929
- Board memberErnesto L. Flores Jan 28, 2025 to now30
- Board memberMario Guillermo Tabraue May 8, 2024 to now24
- Board memberJeff P. H. Cazeau Jul 24, 2024 to now31
- Board memberYovan Arturo Sanchez Dec 12, 2023 to now32
- Board memberGiorgio R. Saumat Nov 22, 2022 to now33
- Board memberGregg Gagan Hunter Dec 6, 2018 to Dec 6, 201825
- Board memberHarvey Katz Mar 30, 2015 to Mar 30, 201520
- Board memberThomas H. Wright May 27, 2015 to May 27, 201526
- Board memberIssa El-Cheikh Apr 16, 2014 to Apr 16, 201421
Former names
- Ultimate Novelty Sports Inc.Feb 1, 2012 to Apr 17, 20144
Timeline
- Sep 1, 20268-K Shareholder vote; Regulation FD disclosure34
- Aug 19, 20268-K Completed an acquisition or sale; Regulation FD disclosure35
- Aug 12, 20268-K Regulation FD disclosure; Other events36
- Aug 7, 20268-K Results of operations37
- Jun 18, 20268-K Results of operations38
- Jun 10, 20268-K Regulation FD disclosure39
- Apr 17, 20268-K Bylaws or fiscal year changed40
- Mar 24, 20268-K Regulation FD disclosure41
- Mar 13, 20268-K Executive or director change42
- Feb 20, 20268-K Change of auditor; Regulation FD disclosure43
- Feb 17, 20268-K Executive or director change; Regulation FD disclosure44
- Jan 6, 20268-K Other events45
- Feb 17, 2023New chief executive Giorgio R. Saumat becomes CEO15
- Dec 6, 2018New chief executive Michel Aube becomes CEO16
- May 19, 2015New chief executive Matthew Cohen becomes CEO17
- Dec 31, 2014New chief executive Harvey Katz becomes CEO18
Calendar
When it reported results
- Aug 7, 2026Reported quarterly or annual results37
- Jun 18, 2026Reported quarterly or annual results38
- Jun 27, 2025Reported quarterly or annual results46
- Jun 20, 2023Reported quarterly or annual results47
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
219 filings to the SEC since October 2021: 8 annual reports, 18 quarterly reports, 65 major events, 108 insider forms, 3 large holders, 3 private raises, 14 other. The latest 20:
- Sep 1, 20268-K EDGAR
- Aug 19, 20268-K EDGAR
- Aug 12, 20268-K EDGAR
- Aug 7, 20268-K EDGAR
- Aug 7, 202610-Q EDGAR
- Jul 29, 2026DEF 14A EDGAR
- Jul 20, 2026PRER14A EDGAR
- Jul 2, 2026PRE 14A EDGAR
- Jun 22, 2026SCHEDULE 13G EDGAR
- Jun 18, 20268-K EDGAR
- Jun 18, 202610-K EDGAR
- Jun 10, 20268-K EDGAR
- Apr 17, 20268-K EDGAR
- Mar 24, 20268-K EDGAR
- Mar 13, 20268-K EDGAR
- Feb 20, 20268-K EDGAR
- Feb 17, 20268-K EDGAR
- Feb 13, 202610-Q EDGAR
- Jan 6, 20268-K EDGAR
- Jan 5, 20268-K EDGAR
The 219 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
117 open-market trades by officers, directors and large owners since October 2021: 117 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 22, 2025 | Saumat Giorgio R.CEO | Buy | 50,000 | $0.21 | $10.5K | Form 4 |
| Jul 21, 2025 | Saumat Giorgio R.CEO | Buy | 100,000 | $0.20 | $20.0K | Form 4 |
| Jul 9, 2025 | Sanchez Yovan ArturoDirector | Buy | 21,939 | $0.18 | $3.9K | Form 4 |
| Jul 8, 2025 | Sanchez Yovan ArturoDirector | Buy | 11,105 | $0.18 | $2.0K | Form 4 |
| Jul 2, 2025 | Sanchez Yovan ArturoDirector | Buy | 60,805 | $0.20 | $12.2K | Form 4 |
| Mar 14, 2025 | Sanchez Yovan ArturoDirector | Buy | 100,000 | $0.12 | $12.0K | Form 4 |
| Mar 10, 2025 | Tabraue Mario GuillermoCOO | Buy | 40,000 | $0.14 | $5.6K | Form 4 |
| Mar 4, 2025 | Rose Christopher AlanCTO | Buy | 31,500 | $0.16 | $4.9K | Form 4 |
| Feb 24, 2025 | Saumat Giorgio R.CEO | Buy | 100,000 | $0.18 | $18.0K | Form 4 |
| Jan 31, 2025 | Sanchez Yovan ArturoDirector | Buy | 100,000 | $0.18 | $18.0K | Form 4 |
| Jan 28, 2025 | Flores Ernesto LCFO | Buy | 43,478 | $0.23 | $10.0K | Form 4 |
| Jan 24, 2025 | Tabraue Mario GuillermoCOO | Buy | 20,000 | $0.23 | $4.6K | Form 4 |
| Jan 16, 2025 | Saumat Giorgio R.CEO | Buy | 783,100 | $0.20 | $155.6K | Form 4 |
| Jan 8, 2025 | Cazeau Jeff P. H. | Buy | 72,555 | $0.15 | $10.8K | Form 4 |
| Jan 7, 2025 | Cazeau Jeff P. H. | Buy | 79,200 | $0.12 | $9.5K | Form 4 |
| Jan 7, 2025 | Cazeau Jeff P. H. | Buy | 79,200 | $0.12 | $9.5K | Form 4 |
| Jan 2, 2025 | Saumat Giorgio R.CEO | Buy | 3,800 | $0.13 | $494 | Form 4 |
| Jan 2, 2025 | Sanchez Yovan ArturoDirector | Buy | 56,151 | $0.12 | $6.7K | Form 4 |
| Dec 27, 2024 | Saumat Giorgio R.CEO | Buy | 600 | $0.14 | $84 | Form 4 |
| Dec 12, 2024 | Sanchez Yovan ArturoDirector | Buy | 100,000 | $0.12 | $12.0K | Form 4 |
All 117 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Giorgio R. SaumatSCHEDULE 13G, 1 filing Jun 22, 202648
- Mario PortelaSC 13G, 1 filing Dec 21, 202249
- Jose Damian RodriguezSC 13G, 1 filing Dec 13, 202250
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2026 | Giorgio R. Saumat | 47 | $1.8M | $3.2M51 |
| 2026 | Mario G. Tabraue | 47 | $1.3M | $2.5M51 |
| 2026 | Ernesto L. Flores | 41 | $160.0K | $370.0K51 |
| 2026 | Christopher Rose | 48 | $270.0K | $290.0K51 |
| 2026 | Victoria Losada | 30 | $202.0K | $250.0K51 |
| 2025 | Giorgio R. Saumat | 47 | $2.6M | $3.6M51 |
| 2025 | Mario G. Tabraue | 47 | $1.9M | $2.5M51 |
| 2025 | Christopher Rose | 48 | $270.0K51 | |
| 2025 | Victoria Losada | 30 | $177.4K | $244.9K51 |
| 2025 | Ernesto L. Flores | 41 | $160.0K | $234.0K51 |
| 2024 | Giorgio R. Saumat | 47 | $2.3M51 | |
| 2024 | Mario G. Tabraue | 47 | $1.3M51 | |
| 2024 | Victoria Losada | 30 | $104.0K51 |
Money raised
Private offerings the company reported to the SEC on Form D.
SEC filer profile
How Earth Science Tech, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGAREarth Science Tech, Inc.1
- CIK0001538495
- Employer ID (EIN)45-42671815
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company5
- Incorporated inflorida5
- Fiscal year endsMarch 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address8950 Sw 74Th Ct, Suite 101, Miami, FL 331561
- Phone(786) 375-72811
- Shares outstanding287,590,881 as of Aug 6, 202614
- Public float$13.6M as of Mar 31, 20265
- AuditorSemple, Marchal & Cooper, LLP, Phoenix, AZ PCAOB ID 1785
- On EDGAR sinceFeb 1, 20121
- Filings403 in all: 8-K (116), 4 (97), 10-Q (37), 3 (19), UPLOAD (19), NT 10-Q (14), CORRESP (13), 10-K (11)1
All 31 form types
10-Q/A (11), 8-K/A (10), 10-K/A (8), S-1/A (8), NT 10-K (6), 3/A (5), 4/A (5), D (4), 10-12G/A (2), EFFECT (2), S-1 (2), SC 13D (2), SC 13G (2), 10-12G (1), 15-12G (1), 8-A12G (1), DEF 14A (1), NT 10-Q/A (1), NTN 10Q (1), PRE 14A (1), PRE 14C (1), PRER14A (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Jun 18, 2026
Quarterly report (10-Q) Aug 7, 2026
Proxy statement (DEF 14A) Jul 29, 2026
Latest 8-K (8-K) Sep 1, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| ETST |
From the cover page of the 10-K filed Jun 18, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Earth Science Tech, Inc. names in Item 1A of its 10-K filed Jun 18, 2026: 62 risks under these headings, as written.5
- Risks Related to Health and Wellness sector
- Our limited operating history and evolving business model make it difficult to evaluate our current performance or predict our future results. Because we are a relatively young company with a developing business model, investors may have limited information on which to base an investment decision. As we continue to grow and expand into new markets and offerings, our prospects must be considered in light of the risks and uncertainties associated with a developing company in a rapidly evolving industry.
- If we are unable to expand the scope of our offerings, our business and financial results may suffer. Our ability to grow depends on expanding the number and types of products and services we offer, increasing the number and quality of healthcare providers on our platform, and broadening the range of treatable conditions. If we fail to do so, our ability to attract and retain customers, generate revenue, and compete effectively may be materially and adversely affected.
- Failure to attract and retain customers may materially harm our business. Our growth depends on acquiring and retaining customers through marketing efforts and platform engagement. If our marketing strategies fail to generate sufficient awareness or demand, or if changes in privacy, healthcare, or marketing regulations limit our outreach, our revenue and overall performance could be negatively impacted.
- Misuse or mismanagement of social media and influencer marketing may expose us to reputational and regulatory risk. While social media and celebrity influencers can enhance brand recognition, any misuse, inappropriate associations, or failure to comply with advertising regulations could lead to reputational damage, customer loss, and potential fines or penalties.
- Our brand is integral to our competitive position, and any deterioration in brand equity could harm our business. We rely heavily on brand strength to differentiate ourselves in the market. If we fail to effectively promote, protect, or maintain our brand, our reputation could suffer, negatively impacting customer acquisition, retention, and partnership opportunities.
- If our offerings fail to achieve or maintain market acceptance, our financial performance could be adversely affected. Failure to meet customer expectations or differentiate our services from competitors could result in slower growth, lower revenue, and reduce investor confidence.
- We operate in a nascent and rapidly evolving market that may be difficult to predict. Our core business model, particularly through Peaks, and Villas, operates in emerging areas of telehealth and wellness. The competitive landscape is dynamic and includes risks related to regulatory changes, industry consolidation, and shifts in consumer behavior, all of which may affect demand forecasting and business planning.
- Technological innovations and alternative solutions may reduce demand for our services. Advancements in digital health, diagnostics, or pharmaceutical therapies could render our offerings less attractive or obsolete, affecting customer retention and revenue.
- We face competition from larger, better-capitalized companies. Many of our competitors include large healthcare systems, retail pharmacies, and pharmaceutical manufacturers with greater brand recognition, operational scale, and financial resources, which may limit our ability to compete effectively.
- Poor customer support may damage our reputation and financial performance. A failure to provide effective support to patients and providers may lead to dissatisfaction, complaints, and erosion of customer loyalty, which could impair our competitive position and revenue.
- Acquisitions and strategic investments could fail to deliver expected benefits and may introduce additional risks. We may pursue acquisitions or strategic partnerships to accelerate growth, but such transactions carry risks related to integration, unforeseen liabilities, operational disruption, and dilution to existing shareholders.
The other 51 risks
- Macroeconomic conditions may negatively affect demand for our services. Economic downturns, inflation, or disruptions in the healthcare or real estate markets may reduce consumer spending or investor confidence, thereby impacting our financial performance.
- Our mobile experience is critical to user engagement and retention. A significant portion of users interact with our platform via mobile devices. Any issues with mobile functionality, performance, or compatibility may impair our ability to retain and grow our customer base.
- We rely on uninterrupted internet and mobile network access to operate our platform. Any outages or interruptions in internet or cellular connectivity could disrupt service availability, reduce customer satisfaction, and harm our reputation. Failures, delays, or breaches by these vendors may impair our ability to provide services, fulfill prescriptions, or maintain operational continuity.
- Supply chain disruptions could affect product availability and customer satisfaction. Delays or shortages in the supply of pharmaceutical ingredients, packaging, or delivery services could affect our ability to meet demand and damage our brand.
- Pharmacy operations are subject to complex healthcare regulations and heightened compliance risk. RxCompound and Mister Meds must adhere to a wide array of state and federal pharmacy regulations, including those beyond telehealth services. Noncompliance could result in fines, license suspensions, or legal action.
- We rely on third-party payment processors and must comply with evolving payment regulations. Any failure in payment processing systems or regulatory compliance could interrupt transactions, harm user experience, and reduce revenue.
- Inaccurate or ineffective pricing strategies could hinder our competitiveness. If our pricing does not reflect market dynamics or customer expectations, we may face reduced demand, margin compression, or lost opportunities for partnership growth.
- Our business depends on the leadership team’s continuity and expertise. The loss of key executives or inability to recruit experienced leadership could impair our ability to execute on strategy and manage daily operations effectively.
- Our growth relies on attracting and retaining skilled employees. An inability to hire or retain qualified personnel may constrain our innovation capacity, operational execution, and scalability.
- We rely on centralized inventory locations for order fulfillment. Our inventory is currently housed at RxCompound’s facility in Miami, Florida and Mister Meds’ facility in Abilene, Texas. A disruption, natural disaster, or facility damage at either site could materially impair our ability to fulfill orders and meet customer expectations.
- Risks Related to Asset Management
- Market volatility could affect asset values and returns. Avenvi’s real estate assets are influenced by macroeconomic factors such as inflation, interest rates, and regional market conditions. A downturn could lead to reduced valuations, delayed projects, and lower development returns.
- Development projects carry execution and cost risks. Delays, cost overruns, zoning or environmental issues, and changing market demand may affect the success and profitability of Avenvi’s development projects.
- Limited access to financing could constrain Avenvi’s growth. Avenvi’s ability to pursue and complete development projects depends on access to capital and credit. Rising interest rates or unfavorable lending terms may limit its ability to fund future activities.
- Avenvi’s performance is closely tied to the Company’s strategic direction. As Avenvi manages physical infrastructure and real estate investments for Earth Science Tech, Inc., changes in ETST’s strategic priorities, capital allocation, or liquidity may directly affect Avenvi’s development operations and financial outcomes.
- Regulatory compliance burdens may increase costs or delay projects. Avenvi’s operations are subject to various zoning, disclosure, tax, and environmental regulations. Changes in these laws may increase compliance costs or restrict development opportunities.
- Shifts in demand may affect project success. Changes in real estate demand—particularly due to economic trends or remote work—may reduce demand for Avenvi’s residential or commercial developments.
- Reputational risks may result from underperformance or mismanagement. Failure to meet development expectations or mismanagement of capital—especially in relation to the Company’s resources—may result in reputational damage or increased scrutiny from shareholders and regulators.
- Risks Related to MagneChef Consumer
- We may be unable to protect our intellectual property rights, including those associated with MagneChef. The MagneChef product line depends on patented technologies and trademarked branding. Failure to enforce or maintain these rights may result in loss of exclusivity, brand dilution, or increased competition.
- Product liability or safety issues related to MagneChef could result in reputational harm or legal exposure. If any Magne product is found to be defective, unsafe, or misused, we may face product recalls, regulatory inquiries, litigation, or consumer dissatisfaction that adversely impacts sales and brand equity.
- MagneChef operates in a competitive consumer goods market with limited barriers to entry. Larger companies with established distribution, pricing power, or marketing budgets may limit our ability to gain or maintain market share.
- Shifts in consumer behavior may impact demand for MagneChef products. Changes in household spending patterns, cooking trends, or consumer preferences could reduce demand and impact overall product performance.
- Risks Related to Governmental Regulation
- We are subject to extensive, complex, and evolving government regulations. Our operations—particularly those involving RxCompound, Mister Meds, Peaks, DOC, and Villas—are subject to a broad range of federal, state, and local regulations governing healthcare, pharmacy operations, telemedicine, and patient privacy. Failure to comply with these regulations could result in substantial penalties, operational restrictions, or reputational harm. Regulatory requirements may change without notice, potentially requiring significant expenditures to ensure compliance.
- Noncompliance with federal or state healthcare laws could result in civil or criminal penalties. If any of our business practices are found to violate anti-kickback statutes, false claims laws, HIPAA, or other healthcare-related laws, we could face fines, exclusion from federal healthcare programs, or other enforcement actions that materially affect our operations.
- Changes in healthcare policy and reimbursement structures could impact our business model. Modifications to federal or state healthcare programs, insurance coverage mandates, or telehealth reimbursement policies may affect customer access, demand for our services, or the financial viability of our offerings.
- Our pharmacy operations are subject to heightened regulatory scrutiny. RxCompound and Mister Meds must comply with numerous state pharmacy board regulations, DEA requirements for controlled substances, and FDA rules for compounded medications. Any violation—whether intentional or inadvertent—could result in license suspension, fines, or criminal investigation.
- Evolving telemedicine regulations create compliance uncertainty. As telehealth laws continue to evolve across jurisdictions, we must adapt to inconsistent requirements around prescribing, physician licensure, patient consent, and record keeping. Failure to keep pace with these changes may limit our geographic reach or lead to regulatory violations.
- Privacy and data protection laws may impose additional burdens on our business. We are subject to HIPAA and other federal and state privacy laws governing the collection, storage, and transmission of personal health information. Breaches or noncompliance may result in fines, litigation, and loss of customer trust.
- Future regulatory developments may increase compliance costs or restrict operations. Emerging policies—such as new FDA oversight of compounded drugs, increased scrutiny of health tech platforms, or restrictions on influencer marketing in healthcare—could materially affect how we conduct business.
- Risks Related to Intellectual Property and Legal Proceedings
- We may be unable to adequately protect our intellectual property rights. Our success depends in part on our ability to protect proprietary technologies, trademarks, trade secrets, and other intellectual property associated with our brands, including MagneChef. If we fail to adequately secure or enforce our rights, we may lose competitive advantages, experience brand dilution, or face increased competition.
- Third parties may infringe on our intellectual property or challenge its validity. Unauthorized use or misappropriation of our intellectual property could harm our reputation and market position. In some cases, we may be forced to initiate costly and time-consuming legal proceedings to protect our rights or defend against infringement claims.
- We may be subject to claims alleging intellectual property infringement. As we expand our offerings, there is a risk that third parties may allege that our technologies, branding, or marketing strategies infringe on their intellectual property rights. Even if such claims lack merit, they could lead to litigation, financial liabilities, or reputational damage.
- Litigation or regulatory investigations could materially impact our operations. We may be involved in legal proceedings or regulatory actions in the normal course of business, including those related to employment practices, patient care, privacy violations, product liability, or contractual disputes. Any such proceedings could result in substantial costs, diversion of management attention, or adverse judgments.
- We may not be adequately insured against certain legal risks. While we maintain liability and business insurance, coverage may be unavailable or insufficient for certain types of intellectual property claims, regulatory actions, or class-action lawsuits. This may result in out-of-pocket expenses that adversely affect our financial position.
- Settlement obligations or adverse rulings could affect financial results. If we are required to settle a legal claim or if a court issues a judgment against us, we could face significant financial liabilities or operational restrictions, which may materially affect our business and results of operations.
- Risks Related to the Company, Results of Operations, and Additional Capital Requirements
- The Company has a history of net losses, anticipates increasing expenses in the future, and may not be able to maintain profitability.
- The Company’s results of operations, as well as our key metrics, may fluctuate on a quarterly and annual basis, which may result in failure to meet the expectations of industry and securities analysts or its investors.
- Peaks relies significantly on revenue from customers purchasing subscription-based prescription products and services and may not be successful in expanding its offerings.
- The requirements of being a public company have strained and may continue to strain the Company’s resources, divert management’s attention, and may result in litigation.
- The Company may require additional capital to support business growth, and this capital might not be available on acceptable terms, if at all.
- If the Company’s estimates or judgments relating to its significant accounting policies prove to be incorrect, the results of operations could be adversely affected.
- Adverse tax laws or regulations could be enacted, or existing laws could be applied to the Company or to customers, which could subject us to additional tax liability and related interest and penalties, increase the costs of the Company’s offerings, and adversely impact our business.
- Certain U.S. state tax authorities may assert the Company has a state nexus and seek to impose state and local income taxes which could harm the results of operations.
- Risks Related to Ownership of the Company Securities
- Our common stock is currently quoted only on the OTCID Marketplace, which may have an unfavorable impact on our stock price and liquidity.
- The regulation of penny stocks by SEC and FINRA may discourage the tradability of our securities.
- Florida law, our Articles of Incorporation, and our by-laws provide for the indemnification of our officers and directors at our expense, and correspondingly limits their liability, which may result in a major cost to us and hurt the interests of our shareholders because corporate resources may be expended for the benefit of officers and/or directors.
- We do not intend to pay cash dividends on any investment in the shares of stock of our Company and any gain on an investment in our Company will need to come through an increase in our stock’s price, which may never happen.
- Because our securities are subject to penny stock rules, you may have difficulty reselling your shares.
- Our common stock market prices may be volatile, which substantially increases the risk that investors may not be able to sell their Securities at or above the price that was paid for the security.
- Because we may issue additional shares of our common stock, investment in our company could be subject to substantial dilution.
- FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our stock.
- The issuance of shares to enter acquisitions may have a significant dilutive effect.
Legal proceedings
From time to time, in the ordinary course of business, we may become involved in legal proceedings seeking monetary damages or other remedies. The ultimate outcome and potential liability, if any, arising from such matters cannot be predicted. As of the date hereof, there are no pending or, to our knowledge, threatened legal actions against us, our officers, or directors in their official capacities, or involving our properties, that, in the opinion of management, are likely to have a material adverse effect on our financial condition, results of operations, or cash flows.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARMichel Aube, Chief executive officer
- 17
- 18SEC EDGARHarvey Katz, Chief executive officer
- 19SEC EDGARNickolas Salomon Tabraue, Chair
- 20SEC EDGARHarvey Katz, President
- 21SEC EDGARIssa El-Cheikh, President
- 22
- 23
- 24
- 25
- 26
- 27SEC EDGAREmiliano Curia, Independent Director
- 28
- 29SEC EDGARDavid Barbash, Chief Sales Officer
- 30SEC EDGARErnesto L. Flores, Board member
- 31SEC EDGARJeff P. H. Cazeau, Board member
- 32SEC EDGARYovan Arturo Sanchez, Board member
- 33SEC EDGARGiorgio R. Saumat, Board member
- 34
- 35
- 36
- 37SEC EDGARResults of operations
- 38SEC EDGARResults of operations
- 39SEC EDGARRegulation FD disclosure
- 40SEC EDGARBylaws or fiscal year changed
- 41SEC EDGARRegulation FD disclosure
- 42SEC EDGARExecutive or director change
- 43
- 44
- 45SEC EDGAROther events
- 46
- 47
- 48
- 49
- 50
- 51